Indefinite Delivery Contract 75N93021D00003
Award Date
10/15/20
Last Date to Order
10/14/27
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Pricing Type
Cost No Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The University of North Carolina at Chapel Hill (UNC) has been awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services. The $146.3 million contract has a period of performance through July 2031 and aims to provide pre-clinical research services to develop and refine animal and animal replacement models for evaluating potential...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Lovelace Biomedical Research Institute to provide preclinical development support for candidate products and drug development activities for HIV, hepatitis, and tuberculosis. The 7-year, $107.3 million contract covers a range of services across seven task areas, including in vitro screening,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded this multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B, hepatitis C, and tuberculosis. The $107.3 million contract has a 7-year period of performance and encompasses seven task areas, including in vitro testing, synthesis of...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027. The contract encompasses a broad scope of work, including in vitro testing and screening, small...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded an indefinite delivery/indefinite quantity (IDIQ) contract to The University of Iowa to provide preclinical development support for HIV, hepatitis B/C, and tuberculosis therapeutic candidates. The IDIQ has a ceiling value of $107,274,471 over a 7-year period of performance from October 2020 to October 2027. The contract encompasses a range of services across seven task areas,...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $40 million indefinite delivery contract (IDC) by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to provide pre-clinical research services related to infectious disease models. This IDC, part of NIAID's "Preclinical Models of Infectious Diseases 2017-2024" program, allows UNC-CH to execute task orders for a variety of research services...
The National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health within the Department of Health and Human Services, awarded multiple Indefinite Delivery/Indefinite Quantity contracts valued collectively up to $364.5 million to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. The ordering period is from December 2021 through November 2028. Under the contracts, the prime contractors will...